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The introduction of chlorpromazine in Belgium and the Netherlands demonstrates an intriguing tango
between old and new treatments. Chlorpromazine, marketed by the French company Rhône Poulenc
entered psychiatry as an adjunct to existing therapies. Instead of promoting chlorpromazine as a revolu-
tionary therapy, we see early efforts to market Largactil as a supplement to the armoury of psychiatric
treatments. These marketing efforts matched the idiosyncrasies of national and local styles and cultures.
Despite continuities with earlier therapeutic developments, we support the notion of a therapeutic rev-
olution. In the early sixties supply and demand provoked a turn towards more standardized therapeutic
regimes.
 2011 Elsevier Ltd. All rights reserved.When citing this paper, please use the full journal title Studies in History and Philosophy of Biological and Biomedical Sciences1. Introduction
Historians generally agree that the introduction of chlorproma-
zine, in 1952, marketed either as Thorazine, Largactil or Mega-
phen, marked the start of a new era of drug treatment in
psychiatry.1 The concept of a therapeutic revolution, however, is a
contested notion as historical evidence points to continuity with ear-
lier therapeutic developments in psychiatry. This study explains the
various ways in which chlorpromazine’s scientiﬁc, medical and cul-
tural proﬁle was established as part of a dynamic health care land-
scape in two neighbouring countries, Belgium and the Netherlands.
This implies accounting for the possible role of chlorpromazine in
redrawing the map of diagnostic and therapeutic regimes in Belgian
and Dutch psychiatric practice—as a prototype of a speciﬁc class of
modern day drugs, antipsychotics. In our paper we will argue that
the introduction and use of chlorpromazine demonstrates an
intriguing tango between old and new treatment features. Histori-ll rights reserved.
nl (T. Pieters), benoit.majerus@uni
–9, Scull (1994), Shorter (1997), p.cally, as a consequence of national and local practices and cultures,
scientists, doctors, nurses, patients and marketers attributed new
features, meanings and identities to chlorpromazine.
Chlorpromazine, pragmatically marketed in Europe by the
French chemical company, Rhône Poulenc, entered Belgian and
Dutch psychiatry as an ad hoc adjunct to existing psychotropic
drug therapies and other bodily cures. Instead of promoting chlor-
promazine as a revolutionary therapy, we see early efforts to pro-
mote Largactil as a supplement to the existing armoury of
psychiatric treatments. We will show how these marketing efforts
matched the idiosyncrasies of national and local styles and cultures
for healing the mind. New therapeutic and diagnostic categories
and the so-categorized patients emerged hand in hand and chan-
ged as material and social conditions changed. Doctors, nurses, pa-
tients, scientists and marketers had to learn to use, cope with and
communicate with each other about a new generation of psycho-
tropics in laboratory, clinic and household settings; redeﬁning.lu (B. Majerus)
255, Weber (1999), Healy (2002), pp. 76–101, Pieters & Snelders (2005), p. 394, Balz
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ratory and clinical measures, and hospital care and outpatient care.
As part of this process of coping with and communicating, drug
standards (as a means of managing the various options for psychi-
atric treatment) had differing value for scientists, doctors, patients
and companies in the 1950s and 1960s. In the 1950s, drug stan-
dards were important only in terms of in-house production and
safety standards for the pharmaceutical industry. Standards for
psychotropic prescription practices ran counter to the established
ﬂexible practice of the materia medica with a strong focus on indi-
vidually tailored drug therapies.2 It was believed that promoting
drug standards would harm commercial standards by alienating
doctors. Not until the sixties did the dynamics of supply and demand
in psychiatry provoke a turn towards more standardized therapeutic
regimes. Issues of governance and control, as we will show, played a
signiﬁcant role in this respect.
2. 4560 RP on probation: shaking cocktails
The French chemical multinational, Rhône-Poulenc, through its
international pharmaceutical division, Specia, distributed the ﬁrst
samples of chlorpromazine under the research label 4560 RP (code
number corresponding to the laboratory synthesis book followed
by the initials for Rhône Poulenc) for clinical investigative use—in
order to determine the range of therapeutic uses and the toler-
ance-toxicity doses—ﬁrst to medical investigators in France and
subsequently abroad during the course of 1951.3 Most common
at the time was a so-called ‘open’ experiment in which the clinical
researcher was held responsible for administering the pharmaceuti-
cal substance to volunteers or patients and monitoring their condi-
tion. There were no ethical committees to sanction (or otherwise)
experiments on humans or formal rules on how to conduct a clinical
trial. Control over testing new pharmaceutical substances was left to
the good sense of the doctors and the pharmaceutical company in-
volved. Based on patient records, the clinical investigator would
form impressions of the potential toxicity—and the probable thera-
peutic value of the substance—and send a summary of the experi-
ment with a conclusion to the trial sponsor.4
One of the protagonists in the development of chlorpromazine,
the French surgeon Henry Laborit, was ﬁrst to recognize the wider
clinical potential of the experimental phenothiazine drug, 4560 RP.
Together with his close companion, the anaesthetist Pierre Hugue-
nard, Laborit pursued the idea of achieving anaesthesia with the
lowest possible dose of the rather risky anaesthetic agents, by
using preoperative medicinal cocktails to potentiate the anaesthet-
ics.5 In the surgery department of Val de Grâce Military-Hospital in
Paris, Laborit suggested a combination formulae and Huguenard pre-
pared increasingly powerful preoperative cocktails. In the process
they observed that cocktails containing hypnotics, analgesics, curare
and a stabilizing antihistamine (e.g. the phenothiazine compound
promethazine) put a body to rest to such an extent that metabolism
was reduced to a minimum and the patient’s temperature dropped
signiﬁcantly to 33-35 degrees Celsius, like a hibernating animal. Pa-
tients treated with these so-called ‘lytic cocktails’, part of a new pro-
cedure of so-called ‘artiﬁcial hibernation’, appeared to be resistant to
operative shock and had an improved recovery from major surgical2 Kraft TB, personal 1950s prescription booklet; series of interviews in preparation of th
3 Swazey (1974), pp. 96–97.
4 Pieters (2005), p. 58.
5 Thuillier (1999), pp.104–105.
6 Thuillier (1999), pp. 107–109, Healy (2002), pp. 81–82.
7 Laborit, Huguenard, & Alluaume (1952), pp. 206–208, Deschamps (1952)pp. 944–946.
8 Delay, Deniker, & Harl (1952a), Delay, Deniker, & Harl (1952b), Hamon, Paraire, & Vel
9 Swazey (1974), p. 134.
10 Interviews with Dutch and Belgian 1950s Specia sales representatives; D. Cannoo, Leide
11 Médecine de France, No XXXVIII (1952), supplementary sheet.interventions. The experimental promethazine-like compound
4560 RP (with an additional chlorine atom) was also tested as a sta-
bilizer in Laborit’s and Huguenard’s lytic cocktails. Adding chlor-
promazine to the cocktails turned out to be remarkably effective
as a component of artiﬁcial hibernation. Furthermore, the new phe-
nothiazine drug not only seemed to potentiate hypnotics and seda-
tives, like the barbiturates, but also potentiated analgesics and had
an anti-emetic effect. Moreover, chlorpromazine seemed to induce
a distinct indifference in stressful pre-surgery patients. Because of
the remarkable wide range of effects or chlorpromazine’s ‘large ac-
tion’, Laborit renamed 4560 RP with the enthousiastic term—‘Largac-
til’. The effects were striking enough to informally share with other
hospital colleagues, such as the psychiatrist Pierre Hamon who was
struggling, on a daily basis, to treat patients under stress with med-
ication cocktails as a component of sleep therapy. Chlorpromazine’s
potentiating capacities would permit the use of a lower dose of
hypnotics and sedatives with an improved margin of safety. The ﬁrst
trial of chlorpromazine in psychiatry, as in surgery, was a combina-
tion treatment in a medication cocktail.6
Throughout 1952, early communications on chlorpromazine’s
stabilizing and potentiating capacities in the ﬁeld of surgery, and
subsequently in psychiatry, were published in the renowned
French medical journals La Presse Medicale and Annales Médico-
Psychologiques, and circulated in France and abroad.7,8 Written
reports on the testing for the experimental drug, 4560 RP, from
well-established psychiatrists, Jean Delay and Pierre Deniker of the
Sainte Anne Hospital in Paris, should have carried considerable
weight. Nevertheless, the Belgian and Dutch response was to wait
and see. Deniker’s presentation at the 50th Congress of the French
Society for Psychiatry and Neurology in Luxembourg at the end of
July 1952 is exemplary as just a handful of colleagues attended the
presentation.9
A growing number of Dutch and Belgian physicians only began
to take notice of the new drug in November 1952, as the drug was
marketed in prescription form as Largactil. Historically, it was
individual contacts between Specia sales representatives and psy-
chiatrists that proved to be the major impetus to move chlorprom-
azine into Belgian and Dutch psychiatry. The marketing campaign
surrounding Largactil’s introduction was modest, even by early
1950s standards. Phenergan (promazine) and Antallergan
(mepyraminum), antihistamines for general practice, as well as
the hypnotic Soneryl (butobarbital) were initially regarded as
far more interesting commercially and received the majority of
the marketing attention.10
The ﬁrst marketing news for the novel drug Largactil (‘large ac-
tion’) appeared in the stylish Specia marketing bulletin Médecine
du France sent to medical specialists with a track-record of pre-
scribing Specia drugs in Belgium and the Netherlands, among other
European countries.11 Largactil (4560 RP) was presented as a new
nervous system modiﬁer, a so-called ‘neuroplegicum’, with a
remarkable broad range of pharmacological effects and potential
broad therapeutic spectrum. However promising as a remedy for
all kinds of nervous system related symptoms and ills (e.g., pruritis,
nausea, and anxiety) the Largactil marketing focus was initially as a
narcotic, hypnotic, sedative and analgesic potentiator: positioning
Largactil as an adjunct to existing medication practices in surgery,e Amsterdam psychotropic drug witness seminar, 08-06-2001.
luz (1952).
n, 7-9-2000; F. Busser, Breskens, 10-9-2000; J. van den Bergh, Antwerpen, 27-10-2000.
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in Belgian and Dutch medical journals was that Largactil would
self-evidently ﬁnd its proper place in medical practice, in terms of
indications and uses (e.g. dosage and forms),‘in the service’ of the
surgeon, obstetrician or psychiatrist.13 Doctors were, so to speak,
invited to pioneer the therapeutic proﬁle of Largactil.3. 4560 RP on trial in Dutch and Belgian psychiatry
The ﬁrst to act on the news in the Netherlands, was Piet
Teenstra, the director and psychiatrist of the Dutch asylum,
Duinenbosch. Teenstra regularly read French medical journals
and maintained close contact with a scientiﬁc staff member of
Barberot Specia, the Dutch sales department of Specia.14 The com-
pany’s showpiece was the powerful antihistamine drug, Phenergan,
used for the treatment of allergies, hypothermia, wounds and stress
reactions. Due to its sedative properties, Phenergan had been suc-
cessfully used as a component in sedative drug cocktails for pro-
longed sleep therapy. This form of physical therapy involved
maintaining unruly and psychotic patients in a continuous sleep
for several days or even weeks; the rational was to give the nervous
system a rest and thereby, a chance to stabilize. Sleep therapy was
practised in Dutch asylum psychiatry on a regular basis from the
1930s onwards.15
Teenstra wanted to test the potentiating effects of this new and
supposedly more powerful experimental 4560 RP compound as it
was closely related to the well-known antihistamine and sedative
Phenergan. He asked Specia for a supply of the still experimental
drug, and obtained it overnight. To the surprise of an inexperienced
young female physician, Nelly-Mary van de Wardt-Kikkert, she
was assigned to test 4560 RP (chlorpromazine) as part of a pro-
longed sleep therapy on the most unruly case in the female
‘chronic disturbance’ pavilion. The ﬁrst Dutch woman to serve as
a research subject was a thirty-two-year-old schizophrenic, who
suffered from hallucinations, voices and insane ideas and had sunk
into an inaccessible aggressive psychotic state. She was so unruly
that she was kept in almost permanent solitary conﬁnement and
straight-jacketed as a means of coercion. Sedation, insulin coma
therapy, and electroshock therapy had all failed to have an effect
on her condition. In a ﬁnal effort to prevent a ‘last-ditch’ surgical
leucotomy she was placed at the top of the trial list for an extra-
strong sleep therapy. Due to a shortage of nurses, however, doctor
Van de Wardt-Kikkert decided not to follow the usual sleep ther-
apy protocol, which required careful patient monitoring over sev-
eral days and even weeks in order to prevent serious breathing
problems. She decided to skip the narcotic component of the sleep
therapy cocktail and test a mono-therapy of chlorpromazine.16
Chlorpromazine was given twice daily by intramuscular injec-
tions in 50-milligram doses. The patient had to be kept in a prone
position for several hours after each injection to avoid problems
with falling due to a sudden decrease in blood pressure. The initial
therapeutic response was remarkable by any standard. The12 Médecine de France, No XXXIX (1953), Largactil (4560 RP) Surgery, obstetrics, p
advertisement.
13 NTvG Largactil advertisement, 21-11-1953; NTvG Largactil advertisement, 06-03-195
1954; Majerus (2010) p. 59.
14 Interview with Mrs. N. M. Van de Wardt-Kikkert, 15-12-2003; Interview with D. J. Ca
15 Schim van der Loeff & Barnhoorn (1947), p. 396, Hamer & Tolsma (1956), pp. 562–56
16 Wardt-Kikkert van de & Rentmeester (1953), p. 501; Interview with N. van de Wardt-
17 Ibid.
18 J. Delay (Ed.) (1956).
19 At this point in time the term ‘pharmacological or fysiological leucotomy’ did not hav
20 Wardt-Kikkert van de & Rentmeester (1953)pp. 504, 505.
21 Psychische en medicamenteuze behandelingsmethoden. Supplementen bij Verslagen d
22 Wardt-Kikkert van de (1956).patient’s behaviour improved signiﬁcantly and she also appeared
to wake up. Over several days she emerged from her psychotic
state and was open to communication. Thereafter she progressed
so rapidly that the staff allowed her to participate in the daily asy-
lum routines and even put her in charge of the female pavilion.
Unfortunately, the patient’s progress halted immediately after
the injections were discontinued due to a late arrival of a new
batch of 4560 RP. Furthermore, the injections caused phlebitis in
the patient and had to be diluted. Despite the reversible nature
of the therapeutic effect and the rather painful injections, the over-
all evaluation was positive. Teenstra decided to scale up clinical
testing as soon as 4560 RP was introduced on the Dutch market
under the trade name, Largactil. In the spring of 1953, a tablet
and suppository form of the drug became available.17
The medical staff of the Dutch Duinenbosch asylum started
administering chlorpromazine in a growing number of female
and male patients who had been unresponsive to other forms of
therapy, regardless of their diagnosis. Although considered to be
a sedative, chlorpromazine appeared to sedate patients in an unu-
sual way. Did chlorpromazine actually deliver an improved sleep
therapy or was there more to it? Sedatives usually put patients
to sleep or cause a lethargic drowsiness but in this case, chlor-
promazine appeared to have a different action. After a couple of
days of drowsiness, chlorpromazine produced a strange but thera-
peutic form of detachment. The resulting drop in patient noise lev-
els was apparent to all professionals working and living in or near
the asylum. Patients on a chlorpromazine drug regimen behaved as
patients who were lobotomized. In accordance with her French and
Belgian colleagues, Van de Wardt-Kikkert called this detachment a
kind of ‘pharmacological lobotomy’.18 But there was more to report
on chlorpromazine than just the ‘lobotomy’ analogy.19 It was specta-
cular that some patients, who had been hospitalised for several years
with chronic psychiatric conditions, opened up for communication
and were receptive to social therapy (‘actieve therapie’).20 On the ba-
sis of this successful early trial, the prescription rate of chlorproma-
zine at the Duinenbosch and neighbouring asylums would rise
exponentially in the course of 1954 and 1955.21 But Van de
Wardt-Kikkert also issued an early warning statement about the
emerging social-psychiatric problem of chronic patients, particularly
women, as they returned to their families after years of absence,
which put a serious burden on their recovery process.22
Frederik Tolsma, a psychiatrist and director of the psychiatric
institution, Maasoord, on the outskirts of Rotterdam, reported sim-
ilar test experiences. Tolsma was also familiar with the sedative
qualities of the closely related drug Phenergan (promethazine) as
a useful co-medication in sleep therapy. He had high expectations
for the more potent fenothiazine analogue chlorpromazine and
started experiments with free samples provided by a Specia sales
representative in the summer of 1953. Unlike Teenstra, Tolsma’s
idea was to reproduce the French artiﬁcial hibernation and stabi-
lize patients’ nervous systems by combining chlorpromazine with
artiﬁcial cooling of the body. Given the lack of expertise for the
complex cooling procedure Tolsma, who wanted his institutionsychiatry advertisement; Médecine de France, No XLV (1953), neuro-psychiatry
4; NTvG Largactil advertisement, 27-03-1954; NTvG Largactil advertisement, 16-10-
nnoo, representative of the scientiﬁc department of Specia, 7 September 2000.
3.
Kikkert, 13 December 2003, Haarlem.
e a negative connotation but rather a therapeutic one.
er Provinciale Ziekenhuizen van Noord-Holland over de jaren 1954 en 1955.
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chlorpromazine as part of conventional sleep therapy.23 Tolsma’s
team of researchers administered chlorpromazine, ﬁrst as a constit-
uent of a medication cocktail, but subsequently, also independently.
A total of 70 chronic psychiatric patients with serious forms of rest-
less and agitated behaviour were treated: 59 female and 11 men. In
53 cases a signiﬁcant therapeutic effect was observed. Exemplary for
the uncontrolled status of the trial is the following case report on the
therapeutic effect in a female patient:
A forty-year-old woman was admitted in 1950. She was very
aggressive, restless and impetuous (. . .) She could hardly be
maintained as part of the wheelbarrow squad. She was initially
given chlorpromazine by intra-muscular injection (daily dose of
150 mg) followed by an oral regimen of 2 tablets three times a
day (daily dose of 150 mg). Currently she is very calm. She has
opened up for communication. She works on a regular basis in
the laundry.24
One of the nurses working at the ‘chronic unrest’ pavilion noted that
within a period of about six weeks after the introduction of chlor-
promazine the unpleasant and aggressive atmosphere changed into
a quiet and peaceful sanatorium. By effectively calming the most
agitated and unruly patients, ‘the terror cases of the institution’,
chlorpromazine was reported to signiﬁcantly reduce the overall
consumption of hypnotics and sedatives at the institution.25 Thus
the chlorpromazine treatment group inadvertently had a therapeuti-
cally beneﬁcial effect on the non-treatment group of patients.
However positive in its clinical assessment, Tolsma’s research
group did contribute some critical remarks. Chlorpromazine did
not have a lasting therapeutic effect. In most cases the disease
symptoms returned as soon as the patients stopped using the med-
ication. Apparently a maintenance dosage was required, but it was
far from clear whether the medication should be maintained for an
indeﬁnite period and what amount sufﬁced to control symptoms.
Despite the fact that no ‘consistently serious’ problems were noted
from the use of the drug, the medical staff observed unwelcome
side effects. In addition to allergic reactions, problematic distor-
tions in blood values and sudden drops in blood pressure were re-
ported. Despite the warning by Tolsma’s group that Largactil
should be handled with caution,26 the message of promise and hope
prevailed in the early Dutch and Belgian reports on the psychiatric
use of chlorpromazine.27
Belgian physicians who ﬁrst used chlorpromazine did so gener-
ally on their own initiative, as in the Netherlands, and requested
information and free drug samples from Specia Rhône Poulenc
after they learned of its therapeutic effects in the French medical
press. However, Specia did not organize clinical trials by selected
high-proﬁle investigators to study speciﬁc actions of the drug in
humans. During the course of 1953 and 1954 a couple of small-
scale ad hoc trials were performed across Belgium. The Brothers
of Charity, who were in charge of the majority of mental hospitals
in Belgium, were the ﬁrst to test 4560 RP on psychiatric patients. In
October 1953 one of the friars reported on the use of this new sed-
ative to treat psychotic patients. The dosage range (50-125 mg/23 Bakker, Blok, & Vijselaar (1999), p. 91, Pieters, Snelders, & Houwaart (2006), p. 53.
24 Tolsma, Jedeloo, & van Kemenade (1954), p. 1000.
25 Ibid.
26 Ibid.
27 Holtzer (1953)pp. 466–467, Boon (1955).
28 Anonymous (1953), p. 26.
29 ‘‘In een paviljoen van onrustige patiënten (. . .) schept ze [de largactilkuur] een sere
largactilkuur een kostbaar, snel werkend en gemakkelijk hanteerbaar hulpmiddel’’, Jacobs
30 Majerus (2010), pp. 63–64.
31 Dutch and Belgian Largactil sales brochures, 1953–1956 (personal archive Toine
representatives, 7 and 10 September 2000.
32 Boon (1955), Rhijn van (1956), Evrard (1958).day) was the same used in the early Dutch trials. And in comparing
the therapeutic effects with insulin coma therapy the ordeal was
rather negative: ‘At ﬁrst glance a largactil treatment is not as
impressive as the insulin treatment’.28 In line with the Rotterdam
group, serious attention was given to side effects and recommenda-
tions made to closely monitor temperature and blood pressure, as
well as the use of gloves by caregivers who distributed the tablets
in order to prevent skin problems. In subsequent reports signiﬁcant
changes due to the use of chlorpromazine on the ward were re-
ported. ‘In effectively calming the most agitated and unruly patients
[. . .] the largactil treatment will change the atmosphere of the
chronic unrest departments.’ Most in agreement with the Dutch re-
ports was a more systematic study by the medical director of one of
the major hospitals in Zelzate, physician Raf Jacobs, who treated a
group of patients with chronic psychosis and another group with
acute psychoses. His ﬁndings were positive for both groups: ‘In a pa-
vilion of troubled patients (. . .) [the largactil treatment] creates a
serene atmosphere of calm and tranquility. For the more acute treat-
able psychoses, the largactil treatment is a precious, fast-acting and
easy tool’.29 He stressed that Largactil could be applied to a wide
range of patients and that the name—Largactil or ‘large action’ of
‘broad’ and ‘activity’—could be considered as justiﬁed. As his Dutch
counterparts had done, Jacobs used the leucotomy analogy to char-
acterize the therapeutic effect. However, his promising account did
not necessarily mean that chlorpromazine was adopted overnight
in Belgian psychiatry.30 Chlorpromazine had yet to prove itself in
both Belgium and the Netherlands
4. A helpful adjunct to local therapeutic biotopes
Specia’s special sales force enabled a growing group of Belgian
and Dutch psychiatrists to test free samples of a drug advertised
as a ‘neuroplegicum’ or ‘neuroplégique’ to achieve a wide spectrum
of therapeutic effects—in almost any pathological condition from
surgical stress to asthma, psychoses and toxicosis in newborns—
by stabilizing the nerve system.31 These free samples were part of
a unidirectional gift economy that had become an important part
of the relationship between pharmaceutical companies and physi-
cians. Thanks to a well-pitched combination of product innovation
and promotion by nationally organized networks of pharmaceutical
sales and scientiﬁc representatives, Specia Rhône-Poulenc had
earned a reputation among Dutch and Belgian doctors by the early
1950s.
Most psychiatrists would give chlorpromazine to their unruly
patients to judge its qualities as an improved form of sleep therapy.
Among others, Jean Bobon chose this testing trajectory in his pri-
vate practice in Liège. Initially he insisted on the use of a cocktail
of barbiturates and Largactil, as he was less enthousiastic about a
Largactil monotherapy. Most psychiatrists in Belgium and the
Netherlands shared the early perception of chlorpromazine (and
later the Rauwolﬁa preparation reserpine (Serpasil), a cheaper
alternative) as an adjunct instead of a cure.32
As far as the medical staff was concerned, the emphasis was on
cautiously integrating chlorpromazine and reserpine into existingne atmosfeer van kalmte en rust. Wat betref geneesbare recente psychosen, is de
(1954), p. 27.
Pieters); interviews with D. Cannoo and Frits Busser, Specia scientiﬁc and sales
Table 1
Evolution of therapy at the Institut de Psychiatrie, Brugmann hospital, Brussels, from 1953 to 1957
1953 (n=18) 1954 (n=59) 1955 (n=52) 1956 (n=36) 1957 (n=36)
ECT 33% 12% 12% 9% 11%
Chlorpromazine 11% 24% 29% 34% 42%
Insulin therapy 17% 15% 2% 0% 3%
Other drugs 61% 59% 85% 63% 75%
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tional somatic treatments, such as shock and sleep therapy, the
new drugs were welcomed as a valuable addition to the existing
armoury of ‘bodily cures’ (see Table 1).
Each institution, asylum or hospital ward had a distinct method
of testing and using chlorpromazine and/or reserpine.34 As a result,
the dose and form of the drug in clinical use varied and depended on
the local psychiatric ‘biotope’. In this respect, chronologies were not
national but local. The largest psychiatric hospital in Brussels, the
Neuro-Psychiatric Titeca Center, did not use neurolepetics until
1956.35 Even inside the nine hospitals managed by the Brothers of
Charity, various time frames existed describing when they began
using chlorpromazine. At the end of 1953, only three out of the nine
Charity hospitals used chlorpromazine. In the course of 1954 the rest
of the Charity hospitals would follow. Chlorpromazine treatment
gradually outpaced other somatic therapies. Exemplary is the total
somatic therapy score for the year 1954 of all the Charity hospitals:
1 lobotomy, 116 insulin treatments, 354 electroconvulsive therapies,
13 treatments of malaria, 285 chlorpromazine (Largactil) therapies
and 104 reserpine (Serpasil) therapies.36 This therapy list does not
provide us, however, any information on the extent to which the var-
ious therapies were combined or not. It was quite common to com-
bine electroshock therapy and chlorpromazine or chlorpromazine
with barbiturates and promethazine (Phenergan) as part of a sleep
therapy.37 But what this systematic record keeping, in this and other
asylums in Belgium and the Netherlands, tells us is that unlike be-
fore, the psychiatrists started reporting on the nature and the effects
of the new drug therapies at both the institute’s and the individual
patient level.38
Specia Rhône Poulenc anticipated the highly idiosyncratic daily
medical practice of pharmacotherapy in Dutch and Belgian asy-
lums and psychiatric clinics by promoting tailored forms of dosag-
ing that would take into account the signiﬁcant variation among
individual patients. They managed differences by embracing the
differences. Specia basically provided informational and technical
support services by providing scientiﬁc information, general ther-
apeutic guidelines and standard dosage forms (25/100mg tablets33 Anonymous (1954), p. 378, Westerink (1956), Dellaert (1956), Timmer (1957), p
medicamenteuze behandelingsmethoden: ‘Largactil’, Verslagen der Provinciale Ziekenhuizen
34 Interviews with the physician (internal medicine) dr. W. Gaulhofer, 3-5-2001 and the p
T.B. Kraft 7-5-2001; and dr. CH. Van Rhijn, 12-6-2001.
35 Missa (2006), p. 309.
36 B.D. (1955).
37 Westerink (1956), p. 121, Majerus (2010), p. 64.
38 The Dutch historian Joost Vijselaar has performed a rather meticulous study of the pa
argues that a major change in the content and nature of the reporting took place following
use was hardly mentioned in the records (which does not imply that drugs were not used o
ninety percent of the patients would receive on a regular base one or the other or multip
39 Anonymous (1961).
40 Even in a Belgian and Dutch article on the pharmacology of chlorpromazine it is claimed
sedative properties; Reuse (1956); Proosdij-Hartzema van EG. (1956); The term ‘psychiat
Gilman´s ‘The pharmacological basis of therapeutics’. According to the Dutch professor in ne
drugs in psychiatry became regarded as a separate pharmacotherapeutic group of substan
41 Tolsma (1956), Rhijn (1960).
42 Wardt-Kikkert van de (1956), p. 403, Schwarz & Marken Lichtenbelt van (1955), Anon
Fuldauer (1959), Rhijn van (1960), Booij (1961); W. Gaulhofer and H. van der Helm, ‘Icteror suppositories, 25/50 mg ampuls, 10mg powder and solution
phials etc).39
Depending on the local culture of treatment and rehabilitation
chlorpromazine or reserpine came to be regarded as either the
most humane form of chemical restraint or as an important aid
to existing social and psychotherapeutic treatment programs.
However, it was not seen as a new form of chemotherapy for the
mind, but rather as a state-of-the-art custom-tailored form of
sedation.40 Chlorpromazine and reserpine were generally regarded
as catalytic agents in a mental recovery process that opened up
chronic schizophrenic patients to communication and social therapy.
Most Dutch and Belgian psychiatrists believed that there was an
essential interplay between the social climate of the setting in which
the drug was provided and the effectiveness of the drug treatment.
Tolsma would even go as far as to create a buddy system in his insti-
tution as a means to stimulate therapeutic optimism and to sustain
chlorpromazine’s favourable therapeutic effects.41
From the very beginning Belgian and Dutch doctors peppered
their testimonies of the beneﬁts of chlorpromazine with critical
assessments of some of the problems associated with its use: from
the social problems associated with the unexpected return of psy-
chiatric patients to their families, to the high frequency of relapses
and side effects. Despite the fact that no ‘consistently serious’ prob-
lems seemed to ensue from the use of the drug, doctors and nurses
alike observed unwelcome side effects. In addition to allergic reac-
tions, problematic distortions in patient blood values and sudden
drops in blood pressure, as well as jaundice, fever and Parkinson-
like symptoms were recorded. They did not refrain from reporting
these clinical problems—although there was little interaction be-
tween the Belgian and Dutch professionals—at the ﬁrst interna-
tional conference on chlorpromazine and neuroleptic drugs in
Paris in October 1955.42
Most outspoken in his critical appraisal was Jacques de Bus-
scher from the University of Ghent, who was also a psychoanalyst
by training. In his opinion, the therapeutic effect was quite often
due to the ‘suggestive inﬂuence exerted by the offer of treatment’
but the question was whether the principle of ‘l’hibernationp. 297–301, Hamer & Tolsma (1964), pp. 207–214, pp. 535–567; Psychische en
van Noord-Holland over het jaar 1955, 1.
sychiatrists dr. P.J. Stolk, 9-5-2001, dr. A.C. Lit, 14-5-2001, dr. A.L. Kroft, 11-5-2001; dr.
tient records in three different Dutch asylums. On the basis of the patient records he
the introduction of chlorpromazine and reserpine. Whereas before psychotropic drug
n a daily basis) drug therapy gradually occupied centre stage. By the end of the 1950s
le chlorpromazine-like drugs; Vijselaar (2010), pp.196–198, pp. 340–341.
to produce therapeutic effects in mental disorders as a result of its antihistamine and
ric drug’ (psychofarmacon) was not yet coined in the 1956 edition of Goodman and
urobiochemistry, Johannes Booij, it was not before the end of the 1950s that the new
ces; Booij J (1961), pp. 158–161.
ymous (1955), Gaulhofer, Schaank, & Vali (1957), Ketel van (1958), Garthier (1958),
us veroorzaakt door chloorpromazine’, Ibid. 105 (1961), 477–481.
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had too much of a ‘Nazi-concentration’ ﬂavour to do good and no
harm.43 However, this idea did not prevent Busscher from prescrib-
ing chlorpromazine and other drugs. The same was true for the
Dutch guest of honour at the Paris conference, the head of the psy-
chiatric department of the medical faculty at Utrecht University,
Henricus Rümke. As a die-hard phenomenologist he hardly men-
tioned using drugs in his writings but as he indicated in his confer-
ence speech, chlorpromazine was welcomed as yet another
pharmaceutical means to the end of therapeutically opening a pa-
tient’s world of experience as a ﬁrst step towards mental recovery.
He shared this approach with Belgian’s pioneer in developing outpa-
tient services for young schizophrenics, René Dellaert from the
University of Leuven.44
From the mid-ﬁfties onwards, Specia Rhône Poulenc and
Ciba began emphasizing the new qualities of chlorpromazine
(Largactil) and reserpine (Serpasil) and differentiating them
from conventional sedatives as nicely reﬂected in the 1956/1957
drug ads. Whereas, Van Gogh´s painting The Round of the Prisoners
was used to promote chlorpromazine’s special relief-producing ef-
fect, the image of a pill superimposed on a brain with the caption
‘different from the barbiturates’ for reserpine, served to underline
the new combination between sedation and mental recovery.45
In order to capture this new therapeutic proﬁle and distinguish it
from sedation, proper Dutch and Belgian psychiatrists began to label
chlorpromazine and reserpine as neuroleptics and/or tranquillizers
from 1956 onwards.465. Towards new treatment concepts and the emerging problem
of a Babel-like confusion
Over time, the inclusion of chlorpromazine and reserpine in dai-
ly institutional drug menus manifested itself as changes in both
treatment and nursing routines. The French procedure of providing
chlorpromazine treatment in combination with bed nursing was
simpliﬁed to drug therapy only. Subsequently, nurses, who had
experienced difﬁculties administering unpleasant-tasting tablets
and an aversion to managing an increasing number of pills, which
often caused severe dermatological reactions, promoted a change
to the use of orange-coated tablets from 1955 onwards.47 The nurs-
ing staff in the Endegeest mental hospital played a seminal role in
the substitution of chlorpromazine tablets for the painful and necro-
sis-producing injections.48 The nursing staff in yet another Dutch
mental hospital, Santpoort, initiated using wide-brimmed hats for
patients taking chlorpromazine to protect their photosensitive skin
against the sun.49 In addition, nurses had to schedule time to shave
female patients who developed chlorpromazine-induced beards.
Nurses also had to address the concerns of patients who did not
use chlorpromazine but had opened up for communication and
therapy and were terrorized by fellow patients.50 Moreover, using43 De Busscher (1956).
44 Rümke, 1956, pp. 39–43, Dellaert (1956).
45 Series of Largactil adds dating from 1957 provided by doctor T. Schok; Medische Docu
46 Proosdij-Hartzema van (1956), Schaepdrijver (1959).
47 Wardt-Kikkert van de (1956), Anonymous (1958).
48 Interview with Dr. Marianne van der Plas, 25 April 2001.
49 Interview with Dr. Thomas Bernard Kraft, 7 mei 2001.
50 Pieters et al. (2006), Blok (1997); Interview with the friar nurse Piet Rooijackers (Heil
51 Praag Van (1966), pp. 47–52, Nijdam (1966), pp. 56–9, 122.
52 Paassen & Ronner (1959). Anonymous (1960).
53 Wertenbroek (1960), Praag Van (1966), Nijdam (1966). Simonart (1961).
54 Majerus (2010), p. 69.
55 Swazey (1974).
56 Majerus (2010), p. 68.
57 Andel (1960).
58 Rhijn (1960).chlorpromazine and reserpine on a large scale required new moni-
toring procedures to check for the daily intake of the medication
and to manage side effects.
The occasional severe side effects—extrapyramidal side effects
(dyskinesias, restlessness, lip smacking movements and parkinso-
nian syndromes), jaundice and even fatal accidents—did not, how-
ever, prevent some psychiatrists from prescribing chlorpromazine
in doses of up to 2000 milligrams daily (average adult dosage 200-
400 mg daily).51 On the contrary, in a number of Belgian and Dutch
mental hospitals, psychiatrists began to use the neuromuscular reac-
tions, closely resembling parkinsonism, induced by chlorpromazine
in patients on higher dosages, as a clinical indicator of optimal treat-
ment.52 Growing support for the idea of a relationship between psy-
chiatric effects and neuromuscular side effects, helped increase the
acceptance of targeted psychotropic agents. Moreover, this idea
stimulated efforts to differentiate drugs like chlorpromazine from
conventional sedatives by creating new categories of psychotropic
drugs including: ganglioplegics, neuroplegics, ataractics, neurolep-
tics, analeptics, psycholeptics, psychoanaleptics, psychodysleptics,
tranquillizers, and subsequently the terms minor and major tran-
quillizers.53 As French and Anglo-Saxon classiﬁcations for psychotro-
pic drugs began to circulate, they were mixed and over time led to a
Babel-like confusion in scientiﬁc communication as well as clinical
communication.54
The Belgian and Dutch enthusiasm for chlorpromazine may not
have been as hyperbolic as in the United States, but a cycle of
promise, hope, therapeutic optimism, subsequent re-evaluation
and disappointment was manifest.55 At the end of the 1950s a
growing number of reports were published in leading medical jour-
nals that assessed the long-term therapeutic beneﬁts of the growing
list of chlorpromazine-like drugs in asylum psychiatry.56 Initial
enthusiasm made way for a critical reassessment of the effectiveness
of chlorpromazine and reserpine. The Dutch psychiatrist, Henk van
Andel, for instance, stated that despite the impressive improvements
in the condition of chronic psychiatric patients, the new drug treat-
ment programs had failed to lower the number of chronic patients in
mental hospitals. On the basis of his experiences at the Dennenoord
mental hospital, Van Andel claimed that this failure was due to the
immense social and cultural gap between the worlds inside and out-
side the institutions.57 His colleague, Cees van Rhijn, who had stud-
ied the neuroleptic-related morbidity and mortality statistics at the
Brinkgreve mental hospital, argued that this very gap contributed to
a signiﬁcant rise in suicides rates.58 In order to safeguard the long-
term therapeutic beneﬁts of neuroleptics, both psychiatrists made
a strong plea for social reforms in mental hospitals and for establish-
ing out-patient clinics with a strong focus on family-guided ap-
proaches to daily care.
A more radical voice could be heart from the director of the
mental hospital in Zeist (‘Het Christelijk Sanatorium’), Adriaan
Lit. In comparing the symptoms of Parkinsonism with the neuro-
muscular side effects of the neuroleptics, he raised the questionmentatie CIBA, no. 1 (1956) 3.
oo), 16 May 2001.
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chemical mask. However important and helpful in clinical terms,
Lit argued that the neuroleptics on an individual patient basis
had a rather general symptomatic and repressive effect that did
not differ signiﬁcantly from the conventional somatic interven-
tions such as shock therapy, sleep therapy and leucotomy.59 In-
stead of a speciﬁc effect on the chemistry of the brain, he qualiﬁed
the chemical effect of chlorpromazine and other neuroleptics as
remarkably non-speciﬁc. Lit’s rephrasing of the early French idea of
a pharmacological leucotomy set the tone for a growing debate in
the 1960s on the pros (e.g. ‘chemical liberation’) and cons (‘chemical
restraint’) of psychotropic drug use in the treatment of mental disor-
ders.60 Until the rise of the anti-psychiatry movement in the 1970s,
however, the message of promise and hope of a new era of psycho-
pharmacology would prevail.61
6. Towards a new ‘chemistry of the mind’
It was the therapeutic and obvious commercial success of chlor-
promazine that stimulated Specia Rhône Poulenc and rival manu-
facturers to develop analogues. By providing a pragmatic and
measurable reference, the pharmacological activity of chlorproma-
zine began to serve as the point of comparison for analogue testing.
Moreover, chlorpromazine was also regarded as the point of refer-
ence for determining the market price, as well as the health insur-
ance reimbursement rate for the scores of phenothiazine
neuroleptics or tranquillizers introduced on the medical market
at the end of the 1950s and beginning of the 1960s.62
Belgian psychiatrists would experience the excitement of test-
ing their own ‘home-grown’ neuroleptic haloperidol—developed
and marketed by the newly established Janssen Pharmaceutica
company in Beerse—which had a rather different chemical and
pharmacological proﬁle than chlorpromazine. At the university
hospital of Liège, Jean Bobon would play a seminal role in showing
that haloperidol was far more potent than chlorpromazine, less
sedative and particularly useful for immediately calming down pa-
tients suffering from an acute and ﬂorid psychosis.63
On the basis of trial and error, doctors tried to ﬁnd the appropri-
ate dose and therapeutic response for the growing number of
chlorpromazine-like drugs available, but this required increasing
expertise to differentiate among the various compounds and to
determine what drug combinations were therapeutically safe and
helpful.64 The call for more therapeutic guidance, drug standards
and laboratory controls became louder in scientiﬁc, medical and
public quarters alike throughout the 1960s.65 Managing similarities
and differences in patient responses was gradually pushed to the top
of the research and clinical agenda.66
In the 1950s, what was still regarded as a signiﬁcant part of the
art of psychiatric doctoring, the materia medica preparation of59 Lit (1959), p. 1296.
60 Sorgdrager (1958), Editorial (1961), Windt (1961), Regensburg (1961), Jong & Kreutzk
61 Pieters & Snelders (2009), p. 69.
62 Majerus (2010), p. 68.
63 In distributing haloperidol for testing purposes Paul Janssen did not select a Dutch in
(1960).
64 Fabius AJM. Jaarverslag Interne-afdeling over de jaren 1967–1968/1969–1970, Psychia
65 Booij J. (1964).
66 Nijdam (1966), Praag (1966), Pieters et al. (2006), p. 89.
67 Pieters et al. (2006), pp. 85–96.
68 Ibid.; Campbell (1971).
69 Booij (1957).
70 Healy (2002), pp. 106–109, Regan (2000), pp. 121–122, Solomon (2001), pp. 22–26.
71 Ban et al. (1998) pp. 23, 51.
72 Original dinner celebration photograph at the 5th CINP meeting March 28 1966, Sher
73 Personal communication Van Rossum 7-11-2008 (born 11-04-1930). In the attic of
chromatographs etc) used in his research work in the 1960s and 1970s.tailored medication cocktails, became increasingly regarded as an
outdated, unscientiﬁc and non-accountable practice by doctors,
patients, regulators, pharmaceutical company and health insur-
ance executives alike. In the wake of the thalidomide drug safety
crisis all parties shared an interest in more consciously weighing
the beneﬁts, risks and costs of pharmacotherapeutic care by the
means of creating drug standards. Polypharmacy was increasingly
criticized for being irrational and irresponsive. In the process labo-
ratory medicine—laboratory sites for monitoring drug effects pro-
liferated in psychiatric hospitals—and epidemiology were making
inroads into Belgian and Dutch psychiatry.67
A horizon, still described by the Dutch psychiatrist Johan Booij
as ‘pharmaco-psychiatry’ in 1957, would become known as the
‘chemistry of madness’ by the mid 1960s.68 The observation that
both chlorpromazine and reserpine counteracted the so-called psy-
chosis induced by the hallucinogenic drug LSD stimulated a differen-
tiation between the conventional hypnotics, sedatives and the new
generation of neuroleptics and tranquillizers.69 By suggesting a rela-
tionship between chemical and clinical psychosis, this observation
created a new scientiﬁc, medical and public horizon of brain chem-
istry and metric in vivo methods for psychopharmacology. LSD, the
experimental tool par excellence and side-by-side with chlorproma-
zine, paved the way for a productive alliance between psychopathol-
ogy and clinical epidemiology that would turn the so-called
‘neurotransmitter revolution in medicine’ into an addictive form of
neurological mythology: the chemically transformable mind.70 The
scientiﬁc debates in the ﬁeld of psychopharmacology had the breath
of a scientiﬁc spring with opportunities for both established scien-
tists and young ambitious newcomers. This was exempliﬁed by the
proceedings of the Washington, DC CINP (Collegium Internationale
Neuro-Psychopharmacologicum) meeting in 1966.71
At the conference dinner, Paul Janssen, the distinguished Bel-
gian pharmacologist and entrepreneur, shared a table with the tal-
ented young Dutch chemist and pharmacologist, Jacques van
Rossum.72 Van Rossum’s earlier work on the relationship between
chemical structure and biological activity had brought him into con-
tact with Janssen, as he elaborated on Janssen’s experimental animal
model for testing potential neuroleptic compounds and their antag-
onism for amphetamine-induced behaviour. With the help of elec-
trophysiological skills and technology acquired during a US
Fulbright Fellowship, van Rossum built a state-of-the-art experimen-
tal system to measure (in a reproducible way) drug receptor interac-
tions in various animal models—experimental manipulation of a
receptor blockade electro-mechanical guidance system in animal tis-
sue.73 Thus he was able to generate a series of reproducible data sets
for possible mechanisms of amphetamine’s psychomotor stimulant
effects at the University of Nijmegen (the Netherlands) from the
early sixties onwards. In the end, at the Washington, DC meeting,
he outlined the hypothesis that neuroleptic drugs act by blockingamp (1961).
vestigator; Healy (2002), pp. 117–123, Symposium International sur le Haloperidol.
trisch Centrum St Willibrord, Heiloo, 1971.
aton Park Hotel, Washington D. C., Capitol Photo, 9822 k2.
his pharmacy in Elst (NL) he still maintains the laboratory equipment (polygraphs,
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even went so far as to argue that if this hypothesis could be further
substantiated, it could have far-reaching consequences for the path-
ophysiology of schizophrenia. If so, then overstimulation of dopa-
mine receptors might contribute to the aetiology of this crippling
disease. Van Rossum added that an implication of the dopamine
hypothesis was that the parkinsonoid side effects of neuroleptics
could not be disconnected from their therapeutic action. Not surpris-
ingly, this correlation was in agreement with the thinking of
Janssen’s close friend, German researcher Hans-Joachim Haase, who
considered the parkinsonoid side effects as a condition sine qua non
for determining the optimal therapeutic dose for a given test. Thus,
Haase had developed a handwriting test for this purpose.76
Van Rossum’s paper reﬂects a remarkable and, in hindsight, a
somewhat naive unity in analytic perspective from an outsider to
the ﬁeld of neuropsychopharmacology.77 Van Rossum’s rather
mathematical and straightforward experimental and reductionist
approach mirrored the systematic way Janssen preferred to tinker
with molecule structures. In 1966 Janssen would propose his ‘phar-
macophore’ concept of a hypothetical chemical structure shared by
neuroleptic agents: the so-called chemical anatomy of neuroleptic
drugs.78 This pharmacophore concept would contribute to the stan-
dardization of the screening for neuroleptic compounds.
The scientiﬁc community of neuropsychopharmacologists
might have been less receptive to Van Rossum’s and Janssen’s con-
ceptual ideas than hoped for, but this did not undermine their
shared optimism that genuine progress was being made towards
the understanding and treatment of mental disease and schizo-
phrenia in particular. A second young Dutch scientiﬁc talent, psy-
chiatrist and psychopharmacologist Herman van Praag,
demonstrated a similar self-conﬁdence at the 1966 CINP meeting.
He had made a name for himself internationally by developing a
structured standard interview for the recognition and registration
of the vital depression symptom complex.79 This work was meant
as a follow up to the Hamilton rating scale for depression. At the
same time, he also showed an interest in neurochemistry with his
work on the metabolism of depressed patients.80
At the time, all three men believed that international standard-
ization of psychopharmacological research tools and of psychotro-
pic drug treatments provided a means to the end for producing
order out of disorder and of developing an evidence-based phar-
maco-psychiatry. The research perspective and lexicon of the
Dutch and Belgian scientists attending the Washington, DC confer-
ence in 1966, differed in major ways from those present at the
Paris conference in 1955.
Whereas in 1955 the researchers involved were, in a large part,
clinical researchers with a strong interest in evaluating the thera-
peutic effects of chlorpromazine, the 1966 group of psychophar-
macologists were, for a large part, laboratory researchers with a
strong focus on the molecular mechanisms of drug action. In their
view the drug responses could and should be objectiﬁed by intro-
ducing reproducible laboratory measures in psychiatric practice.74 Rossum (1967).
75 Although van Rossum was fairly thorough in his presentation of the evidence in the lite
Van Rossum’s reference list. He did not mention an earlier paper by Arvid Carlsson and M
antagonism. But even though Carlsson discovered brain dopamine he did not mention do
76 Haase (1961).
77 According to David Healy, van Rossum was an obscure ﬁgure who had little role in
dopamine work. However, it was his role as a relative obscure outsider that enabled him t
time it ﬂourished to such an extent that it took everyone by surprise. Van Rossum’s contin
world of sport doping in the 1970s; Healy (2002), p. 207.
78 López-Muñoz F. and Alamo C. The consolidation of neuroleptic therapy: Janssen, the dis
79 (2009), 130–141.
79 Praag, Uleman, & Spitz (1965).
80 Praag (1967).
81 Tolsma (1968), p. 120.For the exemplary representative of the 1955 group, the Dutch
psychiatrist Tolsma, however, drug response depended not only
on intrinsic, pharmacological properties of drugs but also on indi-
vidual behaviour and environment. This was exempliﬁed in 1968
by Tolsma’s speech on the occasion of the 15th anniversary of
the introduction of chlorpromazine in the Netherlands. The clinical
pioneer Tolsma pointed out that as any improvement in psychiat-
ric practice, new drug regimes were subject to a gradual process of
‘habituation’ in patients as well as for the medical and nursing
staff. In his view the long-term use of neuroleptics was closely con-
nected with a social tolerance reduction in mental hospitals. Tols-
ma was seriously concerned that what he had coined as ‘a
Copernican revolution in psychiatry’ in 1956, was about to become
bogged down in a continuation of the conventional practice of
maintaining order and quiet.81
7. Conclusion
Tolsma’s cri de coeur shows the ambivalence in the evaluation
of the 1950s ‘psychopharmacological revolution’ that was still vis-
ible in 1968. And as we have shown, he had adequate historical
reasons to doubt calling the introduction of the new drug regimes,
a revolution in Dutch and Belgian psychiatry in the 1950s. As far as
the daily treatment practices are concerned it seems more appro-
priate to speak in terms of evolution. Instead of a rather obvious
departure from the past, we see an intriguing tango between old
and new treatment features. Over time, as part of a trade-off be-
tween old and new (continuities and discontinuities), the success-
ful newcomer helps to reconﬁgure the meanings and the uses of
drug therapy as part of evolving treatment regimes in local thera-
peutic biotopes in Belgian and Dutch psychiatry. All these local bio-
topes learned to use chlorpromazine in their own speciﬁc ways and
at their own pace. Doctors, nurses, patients and marketers all inﬂu-
enced the shifting routines, lexicons and logics surrounding the
uses and understandings of chlorpromazine and its drug ana-
logues. The marketers of Specia Rhône Poulenc strategically put
Belgian and Dutch doctors in charge of producing their own thera-
peutic proﬁles of chlorpromazine as a remedy in the making. In
doing so they successfully aligned the reductionistic laboratory ap-
proach of making drugs with the more holistic and tailoredmateria
medica approach of prescribing drugs in the 1950s. In a historical
perspective this leads to the rather important conclusion that chro-
nologies were not national but local implying that for a better
understanding of the historical development of psychiatric thera-
pies, comparative studies of local practices are required.
As long as doctors, nurses, patients and the marketers of the
pharmaceutical industry were able to narrow the margins of drug
use and interpretation of individual disease conditions to workable
levels by informal means, there was little incentive for more for-
malized standardization. The introduction of sugar-coated tablets,
the incremental changes in the record keeping and nursing rou-
tines were the ﬁrst products of informal and local standardizationrature that supported the dopamine hypothesis, there was an interesting omission in
argit Lindquist (1963), which already alluded to a possible catecholamine receptor
pamine in this paper. Baumeister & Francis (2002).
the further development of the story. Van Rossum indeed did not proceed with his
o bluntly put forward a hypothesis that would not take root until the 1970s at which
ued work on the pharmacokinetics of amphetamines would earn him a name in the
covery of haloperidol and its introduction into clinical practice. Brain Research Bulletin
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dardization was nourished by changes in the supply and demand
of psychotropic drugs in the course of the 1950s. Not until the
highly idiosyncratic ways of using chlorpromazine and the fast
growing number of therapeutic analogues began to show ﬂaws
(e.g., emerging practical problems of monitoring drug safety and
effectiveness in growing numbers of patients and the increasing
intrusion of interests from companies, governments, health insur-
ance and the public), did a more general and permanent need for
formal standardization become manifest in the 1960s.
As a new breed of Belgian and Dutch psychopharmacologists
increasingly began to interfere with psychiatric research in the
1960s, a gradual, but wholesale, transition of therapeutic reasoning
and practice in psychiatry was already under way. This is exempli-
ﬁed by the changing nature and content of the record keeping in the
psychiatric hospitals. Drug therapies moved centre-stage in the
day-to-day treatment of psychiatric patients. Despite the fact that
we point to continuities with earlier therapeutic developments in
the 1950s, there is no reason to contest the notion of a therapeutic
revolution in the wake of the introduction of chlorpromazine and
reserpine in Belgian and Dutch psychiatry. This revolutionary tran-
sitionwas not unlike the current shift to neuroscience and genomics
in the ﬁeld of psychiatry. From pragmatic medical and holistic
phenomenological approaches in psychiatry there was amovement
towards more standardized drug therapy based integrated medical
and social approaches. The gradual acceptance of the ‘chemistry of
the brain’ neurotransmitter concepts would pave the way for the
appropriation of new diagnostic and therapeutic vocabularies and
concepts from the 1970s onwards.Acknowledgements
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